Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
- Conditions
- Thymoma
- Interventions
- Radiation: radiotherapy
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 210
- Registration Number
- NCT02014805
- Locations
- 🇨🇳
Cancer hospital, Chineses Academy of Medical Sciences, Beijing, China
Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT01997372
- Locations
- 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
- Conditions
- Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome, Ph^1^, AbsentB-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: Idarubicin(IDA)
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT01990807
- Locations
- 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Scienses, Tianjin, Tianjin, China
First Line Chemotherapy for Advanced Cancer
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT01980810
- Locations
- 🇨🇳
Department of Medical Oncology,Cancer Hostpital and Institute,CAMS, Beijing, China
Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer
- Conditions
- Squamous Cell Carcinoma of Lung
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01969955
- Locations
- 🇨🇳
Cancer institute and hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Prevention of OM-85 on Bronchiectasis Exacerbation
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 196
- Registration Number
- NCT01968421
- Locations
- 🇨🇳
Shanghai Tongji University, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01939054
- Locations
- 🇨🇳
Xijing Hospital, Xi-an, Shanxi, China
🇨🇳The General Hospital of the People's Liberation Army (PLAGH), Beijing, Beijing, China
🇨🇳Beijing cancer hospital, Beijing, Beijing, China
Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma
- Conditions
- Rectal Neoplasms
- Interventions
- Radiation: preoperative concurrent chemoradiation
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT01930942
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Cisplatin/Capecitabine
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT01928680
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Malignant Neoplasm
- Interventions
- Radiation: chemoradiation
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT01871363
- Locations
- 🇨🇳
Cancer Hospital, CAMS, Beijing, China